HomeCompareRGLS vs YUM

RGLS vs YUM: Dividend Comparison 2026

RGLS yields 24.51% · YUM yields 1.85%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 YUM wins by $11.1K in total portfolio value· pulled ahead in Year 10
10 years
RGLS
RGLS
● Live price
24.51%
Share price
$8.16
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$95.9K
Annual income
$10,627.09
Full RGLS calculator →
YUM
YUM
● Live price
1.85%
Share price
$155.48
Annual div
$2.88
5Y div CAGR
51.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$107.0K
Annual income
$39,957.33
Full YUM calculator →

Portfolio growth — RGLS vs YUM

📍 YUM pulled ahead of the other in Year 10

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRGLSYUM
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RGLS + YUM cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RGLS pays
YUM pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RGLS
Annual income on $10K today (after 15% tax)
$2,083.33/yr
After 10yr DRIP, annual income (after tax)
$9,033.03/yr
YUM
Annual income on $10K today (after 15% tax)
$157.45/yr
After 10yr DRIP, annual income (after tax)
$33,963.73/yr
At 15% tax rate, YUM beats the other by $24,930.70/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RGLS + YUM for your $10,000?

RGLS: 50%YUM: 50%
100% YUM50/50100% RGLS
Portfolio after 10yr
$101.5K
Annual income
$25,292.21/yr
Blended yield
24.93%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on YUM right now

RGLS
Analyst Ratings
9
Buy
9
Hold
Consensus: Buy
Price Target
$7.00
-14.2% upside vs current
Range: $7.00 — $7.00
Altman Z
46.8
Piotroski
1/9
YUM
Analyst Ratings
18
Buy
30
Hold
3
Sell
Consensus: Hold
Price Target
$173.15
+11.4% upside vs current
Range: $158.00 — $190.00
Altman Z
2.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RGLS buys
0
YUM buys
0
No recent congressional trades found for RGLS or YUM in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRGLSYUM
Forward yield24.51%1.85%
Annual dividend / share$2.00$2.88
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.4%
Portfolio after 10y$95.9K$107.0K
Annual income after 10y$10,627.09$39,957.33
Total dividends collected$60.2K$80.4K
Payment frequencyquarterlyquarterly
SectorStockConsumer Discretionary
Analyst consensusBuyHold
Analyst price target$7.00$173.15

Year-by-year: RGLS vs YUM ($10,000, DRIP)

YearRGLS PortfolioRGLS Income/yrYUM PortfolioYUM Income/yrGap
1$13,151$2,450.98$10,980$280.44+$2.2KRGLS
2$17,084$3,012.41$12,185$435.72+$4.9KRGLS
3$21,937$3,657.30$13,722$684.14+$8.2KRGLS
4$27,862$4,389.03$15,773$1,090.14+$12.1KRGLS
5$35,022$5,209.71$18,650$1,773.02+$16.4KRGLS
6$43,593$6,120.11$22,921$2,966.37+$20.7KRGLS
7$53,765$7,119.64$29,685$5,158.69+$24.1KRGLS
8$65,734$8,206.35$41,216$9,453.02+$24.5KRGLS
9$79,713$9,376.98$62,672$18,571.31+$17.0KRGLS
10← crossover$95,920$10,627.09$107,016$39,957.33$11.1KYUM

RGLS vs YUM: Complete Analysis 2026

RGLSStock

Regulus Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease. The company is also developing a pipeline of preclinical drug products for target organ-selective delivery strategies. Regulus Therapeutics Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Full RGLS Calculator →

YUMConsumer Discretionary

YUM! Brands, Inc., together with its subsidiaries, develops, operates, and franchises quick service restaurants worldwide. It operates through four segments: the KFC Division, the Taco Bell Division, the Pizza Hut Division, and the Habit Burger Grill Division. The company operates restaurants under the KFC, Pizza Hut, Taco Bell, and The Habit Burger Grill brands, which specialize in chicken, pizza, made-to-order chargrilled burgers, sandwiches, Mexican-style food categories, and other food products. As of December 31, 2021, it had 26,934 KFC units; 18,381 Pizza Hut units; 7,791 Taco Bell units; and 318 The Habit Burger Grill units in approximately 157 countries and territories. The company was formerly known as TRICON Global Restaurants, Inc. and changed its name to YUM! Brands, Inc. in May 2002. YUM! Brands, Inc. was incorporated in 1997 and is headquartered in Louisville, Kentucky.

Full YUM Calculator →
📬

Get this RGLS vs YUM comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RGLS vs SCHDRGLS vs JEPIRGLS vs ORGLS vs KORGLS vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.